Moving into residential aged care does not end an existing immunoglobulin treatment plan, but it can expose a gap between what a home can coordinate and what an infusion service must deliver. A vacancy is therefore not enough. Before accepting a room, the family needs a written pathway for approvals, appointments, transport, medicines, observations and unexpected delays.
In Australia, government-funded immunoglobulin is governed through national clinical criteria and requests are managed through BloodSTAR. Intravenous immunoglobulin, or IVIg, is usually administered in a hospital or clinic. Subcutaneous immunoglobulin, or SCIg, may be managed differently for a suitable patient under a treating team. Neither arrangement should be assumed from a home's claim that it offers medication support.
Start with the current treatment pathway, not the room brochure
Ask the treating specialist to summarise the diagnosis, product, dose, route, frequency, next review and current administration site. Record the BloodSTAR approval position and the contact details of the hospital, clinic or immunoglobulin program. This creates a baseline against which every home can be tested.
The National Blood Authority's Criteria for the clinical use of immunoglobulin in Australia set out the conditions and circumstances for government-funded access. Requests are assessed against those criteria. An admission manager cannot approve treatment, change eligibility or promise that supply will continue. A home should instead explain how it will cooperate with the authorised clinical team.
Separate accommodation from the place of administration
The central question is where each dose will actually be given. IVIg is usually administered in a hospital or clinic, so a residential aged-care home may be the person's address without being the infusion provider. Ask whether the existing service will continue after the move and whether changing catchment area creates a new referral or appointment process.
If SCIg is being considered or already used, establish who has assessed the resident as suitable, who provides training, who orders supplies and who monitors the treatment. Do not treat SCIg as an automatic way to avoid travel. Capacity, dexterity, cognition, clinical stability and the availability of an appropriately trained person all matter, and the treating team remains responsible for the clinical decision.
Put BloodSTAR approval and review dates on the admission checklist
BloodSTAR is the national online system used to request and manage access to government-funded immunoglobulin. Ask for the current authorisation period, the next review date and any tests or specialist evidence required before renewal. A move close to a review date creates a practical risk: records, pathology and appointments may need to be coordinated while the resident is also settling in.
The home's role should be concrete. Will staff record appointments, help obtain requested observations, share medication records with authorised clinicians and flag a missed review? Ask who owns each action and how the family will be told if an approval, prescription or appointment is incomplete. A vague promise that staff will “take care of it” is not an admission plan.
Compare transport, escort and waiting-time arrangements
For off-site IVIg, map the whole journey. Confirm the infusion location, expected duration, frequency and return time. Then ask whether the resident can use ordinary transport, accessible transport or patient transport under the applicable local rules. Eligibility and availability should be checked, not assumed.
Request a quote for any transport organised by the home and for staff escort time. Clarify whether an escort remains throughout the appointment, who supplies meals and personal care during a long visit, and what happens if the clinic runs late. Compare this with a family-provided escort, but do not build the placement around unpaid help that may not always be available.
Test medication handling without assuming the home holds IVIg stock
Ask the infusion service where the immunoglobulin is supplied, stored and prepared. The home should not imply that it can receive or store a blood product merely because it has a medication room or refrigerator. Product handling follows the authorised supply and clinical pathway.
For a resident using SCIg under an established program, obtain a product-specific plan covering delivery, storage temperature, stock checks, consumables, disposal and excursions outside required conditions. Ask which trained person checks the supply and what happens during a power failure or delivery delay. The answer must match instructions from the treating team and supplier rather than a generic medicines policy.
Price the complete pathway, not the immunoglobulin alone
Eligible patients can receive government-funded immunoglobulin under the national arrangements without a direct charge for the product. That does not make the residential pathway cost-free. Build a monthly comparison that separates the home's basic daily fee and means-tested charges from transport, escorts, additional nursing, appointment coordination, clinical consumables and any pharmacy or delivery charge that may lawfully apply.
Also ask what changes if the person does not meet the national criteria or if a clinician considers a private or direct-order product. The National Blood Authority identifies pathways outside national supply arrangements, but the prescriber and supplier must confirm access and price. A home should never present private supply as guaranteed. Require every optional charge, cancellation rule and review trigger in writing before signing.
Ask how the home handles missed doses and clinical change
The treating team should define what requires urgent clinical advice. The home's admission plan can then specify whom staff call if the resident is unwell, refuses transport, misses an appointment or returns later than expected. Ask how discharge summaries and infusion records enter the home's clinical record and how medication reconciliation is completed.
Do not ask sales staff to predict the medical effect of a delay. Ask them to demonstrate escalation: the contact number used, the senior staff member responsible, the after-hours process and how the family is updated. A provider that can describe this workflow is easier to compare than one offering broad reassurance.
Request evidence of staffing and coordination capacity
Ask who will coordinate the pathway on weekdays and after hours. Relevant evidence may include the home's medication policy, external appointment procedure, handover process, staff competencies and an example of how additional-service charges are authorised. If the home proposes staff involvement in SCIg, the treating program must confirm the tasks and training; a general nursing qualification alone does not answer the product-specific question.
Use a written comparison grid before paying or signing
For each shortlisted home, score the same items: continuity with the current specialist; confirmed infusion location; BloodSTAR review support; transport availability; escort model; record exchange; SCIg capability where relevant; emergency escalation; and itemised extra costs. Mark an answer as “unconfirmed” until the clinical service or funding body verifies it.
Read the residential agreement and fee schedule for clauses on external appointments, additional services, medication management and transport. Ask whether a deposit or other payment is refundable if the agreed immunoglobulin pathway cannot be confirmed before entry. Obtain amendments in writing and keep clinical approval separate from the accommodation contract.
Follow a staged admission process
First, obtain the treatment summary and consent to exchange necessary information. Second, shortlist homes for location, care level and room availability. Third, ask each home to complete the same immunoglobulin questionnaire. Fourth, verify the proposed pathway with the treating service and check the BloodSTAR review timetable. Fifth, request an all-in cost scenario for a normal month and a disrupted month. Only then should the family compare contracts and accept a placement.
Understand placement-service commissions and boundaries
Some placement services receive referral payments from providers, while others charge families or use a mixed model. Ask which homes pay a commission, whether non-paying homes are included, and whether the service has independently verified the immunoglobulin pathway. A referral relationship is not clinical approval and does not prove a vacancy is suitable.
Curalune can help families organise the decision criteria, select options for closer checking and, through its fuller contact service, approach shortlisted providers with the same practical questions. Curalune does not guarantee availability or admission, and it does not replace the specialist, BloodSTAR assessment, infusion service or aged-care provider's clinical assessment.
Frequently asked questions
Can a residential aged-care home administer IVIg?
Do not assume so. National information says IVIg is usually administered in a hospital or clinic. A proposed on-site arrangement must be confirmed by the authorised treating and infusion services, with responsibilities and charges documented.
Does government funding cover every cost after the move?
Government-funded access can cover the immunoglobulin product for an eligible patient under national arrangements. Residential fees, transport, escorts, extra staffing and other services may still create costs. Request an itemised written scenario.
Does moving to another area cancel BloodSTAR approval?
A move does not itself answer the question. Confirm the current authorisation, treating specialist, dispensing arrangements, infusion site and review date with the clinical service before admission. A new service or referral may be needed.
Can the family rely on SCIg to avoid clinic travel?
Only when the treating team has assessed SCIg as appropriate and the full training, supply, storage, monitoring and backup pathway is confirmed. It should not be treated as an accommodation shortcut.